These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7536335)

  • 1. Inhibitory effect of vasoactive intestinal peptide (VIP) on phagocytosis in mouse peritoneal macrophages.
    Ichinose M; Sawada M; Maeno T
    Regul Pept; 1994 Dec; 54(2-3):457-66. PubMed ID: 7536335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages.
    Pozo D; Montilla ML; Guerrero JM; Calvo JR
    Eur J Pharmacol; 1997 Mar; 321(3):379-86. PubMed ID: 9085051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of phagocytosis by adrenocorticotropic hormone in murine peritoneal macrophages.
    Ichinose M; Sawada M; Maeno T
    Immunol Lett; 1994 Oct; 42(3):161-5. PubMed ID: 7534270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoactive intestinal peptide (VIP) inhibits substrate adherence capacity of rat peritoneal macrophages by a mechanism that involves cAMP.
    Segura JJ; Guerrero JM; López-Gonzalez MA; Calvo JR
    Cell Adhes Commun; 1993 Dec; 1(3):213-21. PubMed ID: 7521755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.
    Waelbroeck M; Robberecht P; Coy DH; Camus JC; De Neef P; Christophe J
    Endocrinology; 1985 Jun; 116(6):2643-9. PubMed ID: 2859987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of vasoactive intestinal polypeptide antagonists on cholinergic neurotransmission in dog and cat trachea.
    Xie ZQ; Hirose T; Hakoda H; Ito Y
    Br J Pharmacol; 1991 Dec; 104(4):938-44. PubMed ID: 1667294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of antagonists of vasoactive intestinal peptide on nonadrenergic noncholinergic inhibitory responses in feline airways.
    Thompson DC; Altiere RJ; Diamond L
    Peptides; 1988; 9(2):443-7. PubMed ID: 3131749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: functional and binding studies on opossum internal anal sphincter smooth muscle.
    Chakder S; Rattan S
    J Pharmacol Exp Ther; 1993 Jul; 266(1):392-9. PubMed ID: 8392560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VIP antagonist [N-Ac-Tyr1,D-Phe2]-GRF-(1-29)-NH2: an inhibitor of vasodilation in the feline colon.
    Blank MA; Kimura K; Fuortes M; Jaffe BM
    Am J Physiol; 1990 Aug; 259(2 Pt 1):G252-7. PubMed ID: 2116730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analogue of growth hormone releasing factor (GRF), (Ac-Try1, D-Phe2)-GRF-(1-29), specifically antagonizes the facilitation of the flexor reflex induced by intrathecal vasoactive intestinal peptide in rat spinal cord.
    Xu XJ; Wiesenfeld-Hallin Z
    Neuropeptides; 1991 Mar; 18(3):129-35. PubMed ID: 2067598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect of vasoactive intestinal peptide antagonists on blood flow in the rat thyroid.
    Michalkiewicz M; Huffman LJ; Hedge GA
    Peptides; 1991; 12(6):1181-6. PubMed ID: 1815206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasoactive intestinal peptide receptor antagonists in rat seminal vesicle membranes.
    Rodríguez-Pena MS; Guijarro LG; Prieto JC
    Eur J Pharmacol; 1991 Nov; 208(3):207-12. PubMed ID: 1663044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of vasoactive intestinal polypeptide receptor mRNA and secretory regulation by vasoactive intestinal polypeptide in rat submandibular and sublingual salivary glands.
    Takai N; Yoshida Y; Shida T; Kondo E; Ueda Y; Kiyama H; Tohyama M
    Arch Oral Biol; 1997 Mar; 42(3):197-204. PubMed ID: 9188989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulatory effect of vasoactive intestinal peptide (VIP) on cyclic AMP production in rat peritoneal macrophages.
    Segura JJ; Guerrero JM; Goberna R; Calvo JR
    Regul Pept; 1992 Feb; 37(3):195-203. PubMed ID: 1372999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The action of vasoactive intestinal peptide antagonists on peptidergic modulation of the squid Schwann cell.
    Evans PD; Villegas J
    J Exp Biol; 1988 Sep; 138():259-69. PubMed ID: 3142961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies.
    Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
    J Immunol; 1999 Feb; 162(3):1707-16. PubMed ID: 9973433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages.
    Sun W; Tadmori I; Yang L; Delgado M; Ganea D
    J Neuroimmunol; 2000 Jul; 107(1):88-99. PubMed ID: 10808055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of cholinergic neurotransmission by the peptide VIP, VIP antiserum and VIP antagonists in dog and cat trachea.
    Hakoda H; Ito Y
    J Physiol; 1990 Sep; 428():133-54. PubMed ID: 2172520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A flow cytometric assay reveals a suppression of phagocytosis by rabbit defensin NP-3A in mouse peritoneal macrophages.
    Ichinose M; Sawada M
    Microbiol Immunol; 1995; 39(5):365-7. PubMed ID: 7565178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
    Laburthe M; Couvineau A; Rouyer-Fessard C
    Mol Pharmacol; 1986 Jan; 29(1):23-7. PubMed ID: 3003561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.